David Badcock is the Chief Executive Officer of Drug Science, the leading independent scientific body on drugs in the UK, working to provide clear, evidence-based information without political or commercial interference. Previously David held strategic positions in the substance misuse treatment sector for over 15 years. During this time, he has met and worked with thousands of individuals who have turned their lives around to lead healthy, successful lives free from the burden of drug addiction. He was previously the Chief Executive Officer of Mainliners, a national drug treatment organisation focusing on harm reduction and blood borne viruses.  David has been a committee member for the Cambridge Ethnic Community Forum, Chair of The Alliance (supporting people who receive prescribed medication for drug dependency), and Scientific Committee member for the influential London Joint Working Group for Substance Misuse and Hepatitis C. David specialises in creating unique partnerships with organisations and companies who share a joint vision to help the most marginalised and vulnerable members of our communities.

Dr Anne Katrin Schlag is a Chartered Psychologist and Head of Research at Drug Science. She completed her PhD in Psychology at the London School of Economics and Political Science, before working as Lecturer at King’s College London where she developed her expertise across the spectrum of science and policy making, risk perception, risk management and risk communication. She holds Honorary Fellowships at both Imperial College London and King’s College London.

Within her role at Drug Science, she leads the research for the Medical Cannabis Working Group, focusing on controversies surrounding medical cannabis, the improvement of patient access, and the continued development of education and stakeholder communication about medical cannabis. Dr Schlag is currently working on progressing the scientific evidence base of medical cannabis to include Patient-Reported Outcomes, observational studies (such as T21) and the application of Multi-Criteria Decision Analysis to assess the benefits and safety of medical cannabis.

James Bunn is the Head of Operations for Drug Science. After studying Law at university, he became aware of the injustice and inadequacy of the laws that govern drug policy in the UK. He has worked for multiple charities and Not-for-profit organisations in this field, including Release, The Beckley Foundation, The Students for Sensible Drug Policy and Talking Drugs. He is interested in the therapeutic use of psychedelics, harm reduction, and the dissemination of accurate information relating to psychoactive substances.

Alex Blanchard is the Marketing and Digital Development Officer at Drug Science. He uses modern marketing strategies to develop digital platforms which support drug policy reform and research into therapeutics such as cannabis, MDMA, and psychedelics. Alex has worked with the NHS and various psychedelic research and drug policy organisations, including the Beckley Foundation, OPEN Foundation, and Blossom Analysis. He combines his experience in communications with a degree in Biomedical Science to ensure that complex concepts are accurately conveyed in a manner that resonates with the public.

Consultant neurologist and medical cannabis expert, Professor Mike Barnes has dedicated his career to the development of neurological rehabilitation and medical cannabis awareness, education and clinical excellence.

Professor Barnes brings his expertise to global medical cannabis and CBD wellness organisations, educates clinicians and patients and advocates for a sensible and robust approach to medical cannabis prescribing and industry growth in the UK.

Prof. Michael Lynskey is an epidemiologist and addiction researcher who has held academic appointments in New Zealand, where he’s from, Australia, the United States and the United Kingdom. His research largely focuses on the onset and escalation of drug use during adolescence and he has worked on multiple longitudinal studies examining the assessment of drug related problems and their associations with mental health. Given rapid changes occurring in the regulation of cannabis use and supply, he is increasingly interested in studying policy approaches to cannabis.

Originally trained as a surgeon in the NHS, then 20 years’ senior experience in medical business consultancy spanning medical devices, health services commissioning, clinical transformation, and clinical process redesign. Recent cannabis related appointments include: CMO of the Centre for Medical Cannabis (2018/19) and advisor to many Licensed Producers worldwide.

As Twenty21 Clinical Manager, Mags is the key clinical liaison for Drug Science’s medical cannabis study, helping to grow the knowledge of clinicians in medical cannabis products (CBMP) available for them to prescribe to registered patients. Alongside this, she works closely with Heroic Hearts Project UK, as they grow as an independent organisation and gain charitable status. She also curates and hosts events for The Psychedelic Society (UK) around drug policy, psychedelic science and mental health treatment. Mags’ main goals are to educate and to help change UK drug policy, so that therapies and medicines that are currently not accessible to patients might be made available on the NHS and prescribed to the people who desperately need them.

Dr. Anna Ross is an Honorary Research Assistant at Drug Science, and a Senior Teaching Fellow in Health and Social Sciences at the University of Edinburgh. Anna completed her graduate studies in Law at the University of Edinburgh, followed by a Masters in Alcohol and Drugs Studies, and a PhD in Sociology and drug policy at the University of Edinburgh. Anna has worked for the Scottish Government on developing safeguarding protocol for charities, and the UK Government as the Special Advisor to the Scottish Affairs Committees Inquiry into Problem Drug Use in Scotland. In addition she has been on a range of advisory committees in Scotland, and set up the Scottish Drug Policy Conversations: a multi-stakeholder deliberative group exploring drug policy issues in Scotland.

Rayyan Zafar is an Medical Research Council PhD student studying at Imperial College London in the centre for Neuropsychopharmacology under the supervision of Professor David Nutt. His PhD focuses on the application of multi-modal neuroimaging to understand addictions such as gambling and alcoholism. He has a keen interest in psychopharmacology and particularly how addictions could be treated with psychedelics. Additionally, Rayyan’s current research with Drug science focuses on medical cannabis to treat epilepsy, together with Dr Anne Schlag and Prof David Nutt.

Dr Hannah Thurgur completed a PhD in Neuroscience at the University of Manchester, which investigated the role of inflammation and the extracellular matrix in repair after stroke. Hannah is currently an Executive Officer at the British Neuroscience Association, where she helps represent and promote neuroscience research and neuroscientists across the UK. During her PhD, she became involved with drug policy reform advocacy and developed a strong interest in medical psychedelics. Hannah is also passionate about harm reduction and improved drug education for young people. 

Jacob Aday is a graduate student in the Experimental Psychology program at Central Michigan University. He is in the final year of his Ph.D. and intends to join a laboratory studying classic psychedelic drugs for his postdoctoral training. Within psychedelic science, Jake is primarily interested in delineating the prosocial effects of psychedelics (e.g., increased connectedness, gratitude, nature relatedness, etc.) and studying how these prosocial effects may be beneficial for clinical populations. He also has experience working in cognitive neuroscience laboratories that examine interactions among emotion, attention, and embodiment—as well as the neural correlates of these processes. He is passionate about contributing to the scientific study of psychedelics and the implications findings from psychedelic research can have for drug policy.

Iram Salam is a psychology graduate with a keen interest in mental health, addiction and substance misuse in young people. She is interested in researching the therapeutic use of psychedelics and how psychedelics canbe used to treat addiction and mental health disorders. Iram has previously worked as a Research Assistant for the Christie NHS and currently works with The Conservative Drug Policy Reform Group and Students for Sensible Drug Policy.

Anya is a BSc Psychology graduate from the University of Bristol and is currently doing an MSc in Addiction Studies at King’s College, London. She has a keen interest in harm reduction, drug policy, addiction comorbidities and psychedelic-assisted psychotherapy and hopes to further these interests by pursuing a career in research related to these topics. She currently works to bridge the gap between scientific research and the public, particularly in the case of communicating harm reduction, as well as disseminating academic papers into more digestible forms using social platforms such as Instagram. Anya’s past work experience includes working for various mental health charities including the National Autistic Society and Hullo, involving both research and policy analyst roles.

Plinio graduated with a BSc in Pharmacy and Biochemistry at the University of Sao Paulo and pursued a PhD in Pharmacology also at the University of Sao Paulo. Currently, he works as a Research Associate at the National Heart and Lung Institute, Imperial College London. His main research activities are in the field of Cardiovascular Pharmacology. Since his undergraduate years, he has nurtured a great interest on the field of psychoactive drugs and their relation to the human brain and their impact on society.